Cytokinetics Ownership
Who are the major shareholders and have insiders been buying or selling?
Recent Insider Transactions
Date | Value | Name | Entity | Role | Shares | Max Price |
---|---|---|---|---|---|---|
10 Dec 24 | SellUS$101,300 | Fady Malik | Individual | 2,000 | US$50.65 | |
26 Nov 24 | SellUS$100,280 | Fady Malik | Individual | 2,000 | US$50.14 | |
12 Nov 24 | SellUS$60,936 | Fady Malik | Individual | 1,042 | US$58.48 | |
30 Oct 24 | SellUS$103,860 | Fady Malik | Individual | 2,000 | US$51.93 | |
15 Oct 24 | SellUS$108,400 | Fady Malik | Individual | 2,000 | US$54.20 | |
01 Oct 24 | SellUS$104,220 | Fady Malik | Individual | 2,000 | US$52.11 | |
17 Sep 24 | SellUS$113,520 | Fady Malik | Individual | 2,000 | US$56.76 | |
03 Sep 24 | SellUS$118,830 | Fady Malik | Individual | 2,084 | US$57.02 | |
20 Aug 24 | SellUS$112,460 | Fady Malik | Individual | 2,000 | US$56.23 | |
06 Aug 24 | SellUS$107,400 | Fady Malik | Individual | 2,000 | US$53.70 | |
23 Jul 24 | SellUS$114,040 | Fady Malik | Individual | 2,000 | US$57.02 | |
10 Jul 24 | SellUS$311,245 | Robert Blum | Individual | 5,733 | US$54.29 | |
09 Jul 24 | SellUS$111,780 | Fady Malik | Individual | 2,000 | US$55.89 | |
05 Jul 24 | SellUS$13,816 | Robert Harrington | Individual | 253 | US$54.61 | |
01 Jul 24 | SellUS$621,575 | Robert Blum | Individual | 11,500 | US$54.05 | |
25 Jun 24 | SellUS$107,480 | Fady Malik | Individual | 2,000 | US$53.74 | |
17 Jun 24 | SellUS$1,183,391 | Robert Blum | Individual | 22,500 | US$52.60 | |
11 Jun 24 | SellUS$125,469 | Fady Malik | Individual | 2,366 | US$53.03 | |
10 Jun 24 | SellUS$104,140 | Muna Bhanji | Individual | 2,000 | US$52.07 | |
03 Jun 24 | SellUS$635,978 | Robert Wong | Individual | 13,011 | US$48.88 | |
03 Jun 24 | SellUS$76,851 | Robert Harrington | Individual | 1,580 | US$48.64 | |
09 Apr 24 | SellUS$297,280 | Fady Malik | Individual | 4,000 | US$74.32 |
Insider Trading Volume
Insider Buying: CYTK insiders have only sold shares in the past 3 months.
Ownership Breakdown
Owner Type | Number of Shares | Ownership Percentage |
---|---|---|
State or Government | 46,132 | 0.0333% |
Private Companies | 105,884 | 0.0765% |
Individual Insiders | 580,786 | 0.42% |
Institutions | 137,653,874 | 99.5% |
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.4%.
Top Shareholders
Ownership | Name | Shares | Current Value | Change % | Portfolio % | |
---|---|---|---|---|---|---|
15,252,839 | US$740.2m | 3.95% | 0.01% | |||
12,854,932 | US$623.9m | 22.5% | 0.05% | |||
12,093,859 | US$586.9m | 4.95% | 0.03% | |||
11,761,605 | US$570.8m | 2.83% | 0.01% | |||
7,774,970 | US$377.3m | 3.53% | 0.06% | |||
6,458,324 | US$313.4m | -1.38% | 0.01% | |||
4,687,476 | US$227.5m | 10.5% | 0.07% | |||
2,848,584 | US$138.2m | 4.01% | 0.01% | |||
2,721,158 | US$132.1m | 0% | 1.91% | |||
2,337,847 | US$113.5m | -4.76% | 0.4% | |||
2,100,000 | US$101.9m | 0% | 7.09% | |||
2,088,567 | US$101.4m | 18.1% | 0.09% | |||
1,896,575 | US$92.0m | -8.2% | 2.09% | |||
1,873,701 | US$90.9m | 11.7% | 0.13% | |||
1,757,192 | US$85.3m | 0% | 5.58% | |||
1,661,014 | US$80.6m | -11.6% | 0.02% | |||
1,500,000 | US$72.8m | -27.7% | 5.84% | |||
1,329,654 | US$64.5m | 3.64% | 0.01% | |||
1,321,391 | US$64.1m | 42.8% | 0.01% | |||
1,212,886 | US$58.9m | 38.9% | 0.25% | |||
1,212,258 | US$58.8m | -27.7% | 7.29% | |||
1,165,432 | US$56.6m | 52.9% | 0.07% | |||
1,143,830 | US$55.5m | 17.2% | 0.02% | |||
1,110,000 | US$53.9m | 0% | 13.3% | |||
1,100,000 | US$53.4m | -1.7% | 1.04% |
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/26 07:39 |
End of Day Share Price | 2024/12/26 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cytokinetics, Incorporated is covered by 36 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Carter Gould | Barclays |
Jason Zemansky | BofA Global Research |
Mayank Mamtani | B. Riley Securities, Inc. |